
AFRICAN START-UP PITCHES



Conrad Tankou CEO **GIC Space**














PLATINUM SPONSOR



CITY PARTNER








3 months to seek care

3 months to get a diagnosis



CENTRE PASTEUR DU CAMEROUN

EXAMEN MICROSCOPIQUE

Les deux nodules montrent des lésions identiques. Le matériel examiné montre au sein d'un tissu mammaire une prolifération tumorale maligne faite de cellules glandulaires atypiques. Ces cellules sont disposées en massifs cellulaires. On note un pléomorphisme cellulaire marqué. Les noyaux sont arrondis ou ovalaires, hyperchromatiques d'aspect granulé avec 1 à 2 nucléoles visibles. On dénombre 7 figures de mitoses sur 10 champs au fort grossissement. Il s'y associe de nombreux foyers de carcinome in situ de haut grade avec comédonécrose.On ne note pas d'emboles vasculaires péritumoraux. Les remaniements fibreux contiennent de nombreux foyers de carcinome in situ de haut grade. La limite supérieure est infiltrée. Les 2 nodules parvenus dans le deuxième contenant correspondent à des ganglions infiltrés.

CONCLUSION

Pièce de nodulectomie avec curage axillaire montrant des aspects histopathologiques de carcinome canalaire de grade III de Nottingham avec un score de Scarff-Bloom et Richardson modifié par Elston et Ellis 8 (3+3+2):

Confirmed

breast cancer

- -Absence d'emboles péritumoraux :
- -Présence de carcinome in situ avec comédonécrose -Limite supérieure infiltrée:
- -absence de maladie de Paget et d'extension rétro-mam
- Classification pTNM (AJCC, Bème édition 2017)= pT2 pharms, a fine drogoniste dans notre laboratoire est souhaitable à la recherche de la surexpression du Her2 et des récepteurs hormonaux.



In SSA overall prevalence of breast cancer screening = 12.9% only

9 in 10 women who die from cervical cancer are in developing countries



31% Breast Cancer



23% Cervical Cancer



Scarcity of medical specialists



Lack of access (currently 5%)



90% discovered at late or end stage



...remote screening at the point of care!





Digital microscopy system/Telepathology



Fine needle biopsy device



Telemedicine platform



Gamified 3D platform



#Adaptable

#Reliable

#Faster


#PointOfCare

#Affordable

GICMED

3D Gamified learning/training For health providers + general population







#Intuitive

#Captivating

#Engaging

#Offline

#Easy

#Linkage to care

#Self pace

Screening process...

1. Required data captured at the point of care with GICMED Tech



3. Results Received at the point of care

24-72 hrs vs 1- 4 Months












2. Instant review and diagnosis by a Specialist





#PointOfCare

#Faster

#Cheaper

Treatment options







Tracking patients to the nearest treatment facility


(advanced cervical lesions + breast lesions)

Mobile treatment unit system with thermocoagulation

(early-stage cervical lesions)




Our implementation model



Business Model



Providing/Leasing Technologies to Hospitals








	GICMED	Specialized Hospitals	Mobile OTD (East Africa)
Cost	1	×	×
Both Breast and Cervical Cancers	1	1	×
Speculum + colposcope in 1 device	1	×	×
E-Records	1	×	1
Patient tracking	1	×	1
Access to treatment	1	1	×
Enables remote examination in real time	1	×	1
Faster examination time	1	×	×
Enables 2nd and 3rd opinions	1	×	1

Particularly adapted to the African context!



Traditional Speculum Poor visibility, patient discomfort		Our Smart Speculum Significant increase visibility, NO patient discomfort		
Image of cervix	Pain level	Image of Cervix	Pain level	
1	4	A	0	
		DAY NO COURS		
WILD VE	•		U	
			No	
	Moderate Pain		Pain	
4/45	6	ATTA	0	
		Market State of the State of th		
Section 20				
The second		MIT STORY	No Pain	
The contract	Severe Pain	1000	3,777//	
	4		0	
197				
			3	
15/16		1	No	
	Moderate Pain	1	Pain	



I honestly think every hospital should adopt C-Spec by GICMED. The level of comfort for women is highly remarkable. And I got to see my cervix in real time.

Geraldine.

Client

I have never seen my patients as comfortable as they are now during speculum examination. This is really a revolution in FemTech.

Dr Tahtah Fritz

Doctor

Having a Colposcope and a speculum in one portable and easy to use device, what more to say about such an ingenious product.

Dr Solomon A.

Doctor



Target Women aged between 21 years + = 400M+

Target health facilities = 500k+











Cervical Cancer





Female Genital Schistosomiasis





THANKS!

E-mail: info@gictelemed.org

Phone: +237 691 89 61 65

Web: www.gictelemed.org

